Impact of PCSK9 Inhibitor Recaticimab on Hyperlipidemia and Plasma Glucose: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study.
Recaticimab showed no adverse glycemic effects in participants with normal or abnormal glucose metabolism, indicating its safety in patients with or without diabetes.
Authors
- Chen Chen (ORCID: https://orcid.org/0000-0003-1406-5721)
- Shujun J. Zhang (ORCID: https://orcid.org/0000-0001-6139-6887)
- Xiao hui He
- Xuanyin Wang (ORCID: https://orcid.org/0000-0002-4885-1280)
- Ye Hu
Institutions
- Nanchang University (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Beijing Luhe Hospital Affiliated to Capital Medical University (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-10-20
- DOI
- https://doi.org/10.3967/bes2025.123
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00